Drugs / balicatib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00170911 | Mar → Dec 2005 | osteoporosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00371670 | Dec 2004 → Jul 2006 | osteoarthritis, knee | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00100607 | Feb 2004 → Sep 2005 | osteoporosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | balicatib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00371670 ↗ |
| Known as | AAE581 | “balicatib (AAE581)” NCT00371670 ↗ |
| Action | Inhibit | “AAE581 is a specific inhibitor of the cysteine protease cathepsin K.” NCT00170911 ↗1“Cathepsin K inhibitor” CHEMBL371064 ↗ |
| Modality | Small molecule | — CHEMBL371064 ↗ |
| Target | CTSK | “Cathepsin K inhibitor” CHEMBL371064 ↗ |